ClinicalTrials.gg
DrugRead study by study

Lenvatinib clinical trials

Also written Lenvima, E7080 and MK-7902.

studies test it
431
open now
181
in phase 3
43
first study started
2005
ClinicalTrials.gov finds 696 studies for lenvatinib. How that becomes 431 here

Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives lenvatinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 696Found by its intervention search · See all 696 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 588 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −13
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −1New since the last reading, not read yet
  4. 682Give lenvatinib to participants
  5. −74Observe patients on it, or give it outside a trial
  6. −2Use it as a tool: an imaging tracer or a test of drug response
  7. −8Compare another treatment with it
  8. −167Give it beside what is tested
  9. 431Test it: the count on this site

Get an email when these change. Save the lenvatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Feb 2015 · LENVIMA · NDA 206947 (FDA, Drugs@FDA)
European Union
28 May 2015 · Lenvima · EMEA/H/C/003727 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lenvatinib
251
Multi-Kinase Inhibitor E7080
15
Lenvatinib Mesylate
8
E7080, Lenvima
8
4-[3-Chloro-4-(N''-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate
4

Brand

Lenvima
78

Development codes

E7080
74
MK-7902
26
ER-203492-00
13

In one entry with another drug

Given together, or one or the other

pembrolizumab and lenvatinib
4
Lenvatinib + Letrozole
2
Tislelizumab, Lenvatinib
2
Pembrolizumab plus Lenvatinib
2
Pucotenlimab Combined with Lenvatinib
2
Tislelizumab combined with Lenvatinib
2
Lenvatinib plus pucotenlimab
2
levima plus pucotenlimab
2

Studies by the year they started

430 studies that test it; most in 2021 (52); 1 more planned to start later

Studies that test lenvatinib, by start year
YearStudies
20052
20061
20081
20093
20108
20118
20121
20133
20142
20157
201612
201712
201821
201930
202037
202152
202251
202348
202443
202539
202649

By phase

A phase 1/2 study counts in both.

Early Phase 1
8
Phase 1
70
Phase 2
312
Phase 3
43
Phase 4
12
No phase
25

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 81 · Other 350

Eisai Inc. (35) · Sun Yat-sen University (34) · Merck Sharp & Dohme LLC (26) · Tianjin Medical University Cancer Institute and Hospital (20) · Fudan University (19) · Shanghai Zhongshan Hospital (15) · Peking Union Medical College Hospital (14) · Eisai Co., Ltd. (12)

Often tested with

Tested in the same studies.

Pembrolizumab (97) · Tislelizumab (29) · Sintilimab (23) · Durvalumab (13) · Immune checkpoint inhibitors (13) · Toripalimab (12) · Iparomlimab/Tuvonralimab (10) · Nivolumab (8)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Lenvatinib is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with lenvatinib beside them; studies of each.

Reaching primary completion within a year · 62, 3 in phase 3

Studies that test lenvatinib, phase 3 first.

Studies

Open first, then newest update. How each study uses lenvatinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 431

See all 431 studies that test lenvatinib →

Behind its US label · 6 — the studies the FDA label of LENVIMA describes

From the Clinical Studies section of LENVIMA (2026-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 79 — no other medicine in its arm

Showing 20 of 79. See all 79 →

Tested with established drugs · 43 — they are given beside it

Showing 20 of 43. See all 43 →

Tested in a combination · 307 — another drug in the study is under test too

Showing 20 of 307. See all 307 →

Beside an established treatment under test · 55 — an approved drug, surgery or radiation is what the study tests

Tested with lenvatinib: Surgery or a procedure 21 · Radiation 13 · belzutifan 3 · Immune checkpoint inhibitors 3 · atezolizumab 2 · tislelizumab 2 · pembrolizumab 2 · Lenalidomide 1

Showing 20 of 55. See all 55 →

Beside a new treatment under test · 104 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with lenvatinib: Pembrolizumab/Quavonlimab MK-1308A 7 · Anti-ILT4 Monoclonal Antibody MK-4830 5 · cadonilimab 5 · favezelimab 5 · H-101 5 · belzutifan 4 · tislelizumab 4 · toripalimab 3

Showing 20 of 104. See all 104 →

Beside supportive care · 2 — a supportive treatment or test is studied
One option of several · 5 — a test or a strategy chooses among drugs
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 8 — what is tested is compared with lenvatinib
Observed · 74 — patients on it are followed, or it is given outside a trial

Showing 20 of 74. See all 74 →

As a tool · 2 — an imaging tracer or a test of drug response

Codes

What other systems call lenvatinib · ClinicalTrials.gg INT005329

  • MeSH (NLM) C531958lenvatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) EE083865G2LENVATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1603296Confirmed FDA, Wikidata
  • Wikidata Q6523413lenvatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C95124LenvatinibOne source FDA
  • DrugBank DB09078One source Wikidata

Also registered as 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (UNII 269N24780P) and lenvatinib mesylate (UNII 3J78384F61 · RxNorm 1604346).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion